Company: DERM
Filing Date: 2025-08-28
Form Type: 424B3
Source: 0001104659-25-084876
Chunk: 13

Company: Journey Medical Corp
Filing Date: 2025-08-28
Form: 424B3
Chunk 13
---
 New risks and uncertainties
arise from time to time, and it is impossible for us to predict these events or how they may affect us. Except as required by law, we
assume no responsibility for updating any forward-looking statements.

We qualify all of the information presented in
this prospectus supplement, the accompanying prospectus and any document incorporated herein by reference, and particularly our forward-looking
statements, by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection
of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

<div align='center'>S-8

USE OF PROCEEDS</div>

We may issue and sell up to 3,750,000 shares of
our common stock from time to time. Because there is no minimum offering amount required as a condition to close this offering, the actual
total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. There can be no assurance that
we will sell any shares under or fully utilize the Sales Agreement with the Agents as a source of financing.

We currently intend to use the net proceeds from
the sale of any securities offered under this prospectus supplement for general corporate purposes unless otherwise indicated in the applicable
prospectus supplement. General corporate purposes may include working capital, research and development, payments for research and development — licenses
acquired, sales and marketing activities, general administrative matters, operating expenses and capital expenditures. We may also use
a portion of the net proceeds to acquire or invest in businesses, products and technologies that are complementary to our own, although
we have no commitments or agreements with respect to any acquisitions as of the date of this prospectus supplement. Pending these uses,
we may invest the net proceeds in a variety of capital preservation instruments, including short-term, investment-grade, interest-bearing
instruments and U.S. government securities, or may hold such proceeds as cash, until they are used for their stated purpose. We have not
determined the amount of net proceeds to be used specifically for such purposes. As a result, management will retain broad discretion
over the allocation of net proceeds.

<div align='center'>S-9

DILUTION</div>

If you invest in our common stock, your interest
will be diluted to the extent of the difference between the price per share of our common stock you pay in this offering and the as adjusted
net tangible book value per